Kirby McInerney LLP Announces Investigation of Possible Claims Against Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

Core Insights - Aldeyra Therapeutics is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and unlawful business practices [1][3] - The FDA issued a Complete Response Letter for Aldeyra's New Drug Application for reproxalap, indicating that the application did not demonstrate efficacy in treating ocular symptoms associated with dry eyes [3] - Following the FDA's announcement, Aldeyra's stock price plummeted by approximately 73%, dropping from $5.32 to$1.42 per share [3] Company Developments - The investigation by Kirby McInerney LLP focuses on whether Aldeyra and its officers engaged in unlawful practices [1] - The FDA's concerns regarding the NDA included methodological issues and differences in baseline scores across treatment arms [3] - The significant decline in share price reflects investor reaction to the FDA's findings and the implications for Aldeyra's lead drug candidate [3]